egnite and JenaValve partner to assess prevalence of aortic regurgitation in USA


egnite and JenaValve Technology have announced a strategic partnership aimed to offer insight on the care paradigm and associated outcomes of patients with aortic regurgitation (AR).

In a press release, the companies said that the partnership will leverage egnite’s database to quantify prevalence and treatment patterns, estimating that there may be over 500,000 patients in the USA diagnosed with moderate or severe AR.

Duane Pinto, chief medical officer of JenaValve, said: “By utilising cutting-edge analytics and JenaValve’s innovative transcatheter therapies, we hope to drive urgent change, provide improved treatment options, and ultimately save lives. These findings also provide valuable insights for healthcare providers and policymakers, encouraging further attention toward improving outcomes for patients suffering from AR.”

Interventional cardiologist Nicholas S Amoroso (Medical University of South Carolina, Charleston, USA) presented the first study from this partnership at TVT 2023 (7–10 June, Phoenix, USA). The novel study examined two-year treatment rates and outcomes for patients with AR utilising over 1 million patients from 25 leading teaching and non-teaching cardiovascular programmes across the USA from egnite’s database.

Key findings uncovered that despite high two-year mortality rates and guideline indications for treatment, patients with severe AR received low rates of specialist evaluations and treatment with aortic valve replacement. The study also demonstrated that patients diagnosed with moderate or severe AR and severe left ventricular dilation exhibited similar mortality rates, suggesting that some patients may benefit from earlier assessment by the heart team.

“This is one of the first artificial intelligence-driven studies providing critical insights into care patterns for patients with moderate or greater AR in the community,” stated Amoroso. “The urgency for digital technologies to identify AR patients earlier and novel therapies to improve outcomes for this vulnerable patient population has never been greater.”


Please enter your comment!
Please enter your name here